ARCHIVES

ODAC Rejects Temodal for Melanoma After Discussion Of Approval Standards

This article is from The Cancer Letter archive.

Vol. 25 No. 13 | April 2, 1999

Download PDF Visit The Full Archive

Related Articles

Two-Week Break Balances RT Palliation, Side Effects

February 26, 2010

ACCC Annual Meeting To Study Organizing Community Care

January 26, 1979

Gleevec Approval Sets Record For FDA Review: 73 Days

May 25, 2001

In Brief: Louisville Cancer Center Developed With No Federal, State Money Or Fund Raising Costs

May 30, 1980

NSABP Submits Appeal To NIH To Reverse Cancellation Of P-4 Chemoprevention Trial.

August 10, 2007

Coalition Gives “Incomplete” To NCI, CDC Statistics, But Gets Low Grade From Critics

March 20, 1998